ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase III clinical study for timdarpacept (IMM01), the first SIRPαFc fusion protein targeting CD47 to be designed in China. The study will evaluate the safety and efficacy of IMM01 in combination with azacitidine for the treatment of first-line high-risk myelodysplastic syndrome (HRMDS).
IMM01 was independently discovered and developed by ImmuneOnco utilizing its proprietary “mAb-Trap” technology platform. This drug candidate, which operates through a dual mechanism, has exhibited potent anti-tumor activity. With its unique molecular design, IMM01 has shown a favorable safety profile and has been confirmed to effectively activate macrophages, a key component of the immune system.- Flcube.com
